| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Agouron Pharmaceuticals |
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002169 |
Purpose
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.
| Condition | Intervention | Phase |
|
Cytomegalovirus Retinitis HIV Infections |
Drug: Nelfinavir mesylate |
Phase II |
| MedlinePlus related topics: | AIDS Cytomegalovirus Infections |
| Drug Information available for: | Nelfinavir Nelfinavir Mesylate |
| Study Type: | Interventional |
| Study Design: | Treatment, Placebo Control, Safety Study |
| Official Title: | A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection |
Eligibility
| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
Exclusion Criteria
Prior Medication:
Excluded:
Prior therapy (or less than 2 weeks) with protease inhibitor other than saquinavir.
Contacts and Locations| United States, California | |||||
| Harbor UCLA Med Ctr | |||||
| Torrance, California, United States, 90502 | |||||
| Univ of California / UCI Med Ctr | |||||
| Orange, California, United States, 92868 | |||||
| Univ of California / San Diego Treatment Ctr | |||||
| San Diego, California, United States, 92103 | |||||
| Univ of Southern California / LA County USC Med Cntr | |||||
| Los Angeles, California, United States, 90033 | |||||
| United States, District of Columbia | |||||
| George Washington Univ | |||||
| Washington, District of Columbia, United States, 20037 | |||||
| United States, Illinois | |||||
| Northwestern Univ / SOCA | |||||
| Chicago, Illinois, United States, 60611 | |||||
| United States, Texas | |||||
| Univ of Texas Med Branch | |||||
| Galveston, Texas, United States, 77555 | |||||
| Baylor Univ | |||||
| Houston, Texas, United States, 77009 | |||||
| Agouron Pharmaceuticals |
More Information
| Study ID Numbers: | 259A, Study 517, AG1343-517 |
| First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002169 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
|
